4-[18F]氟苄基右旋苄哌苯哌酮的人体生物分布与内照射剂量学:一种用于脑和心脏毒蕈碱乙酰胆碱受体显像的PET放射性药物
该研究基于多次全身PET/CT显像评估了4-[18F]氟苄基右旋苄哌苯哌酮(F-DEX)在人体内的生物分布、器官示踪动力学及辐射剂量,采用ICRP 133标准男性和女性数学模型计算S因子,结果显示平均有效剂量为19.70 ± 2.27 μSv/MBq,与FDG(19.0 μSv/MBq)相当且低于SPECT显像剂I-DEX(28.5 μSv/MBq)。作者认为剂量优化后临床使用有效剂量可能低于4 mSv,F-DEX是脑毒蕈碱受体显像的有吸引力的选择,并可能值得进一步研究其用于心脏副交感神经支配显像的潜力。
要点
- F-DEX的平均有效剂量为19.70 ± 2.27 μSv/MBq,与FDG(19.0 μSv/MBq)相当,低于I-DEX(28.5 μSv/MBq)。
- 脑和左心室心肌摄取分别占注射活性的5%和0.65%,脑内滞留高于心肌。
- 标准男性肝脏吸收剂量最高(52.91 ± 1.46 μGy/MBq),标准女性肝脏最高(61.66 ± 13.61 μGy/MBq)。
核心结论
- F-DEX给药相关的辐射剂量与其他18F标记示踪剂如FDG(19.0 μSv/MBq)相当,且低于用于毒蕈碱受体SPECT显像的示踪剂I-DEX(28.5 μSv/MBq)。
- 对于ICRP 133标准体模,剂量优化后临床使用有效剂量可能低于4 mSv,从而支持多次随访检查的合理性。
- 近期首次人体研究结果和相对较低的辐射剂量使F-DEX成为未来脑毒蕈碱受体显像应用的有吸引力的选择。
- 可能值得进一步研究F-DEX用于心脏副交感神经支配显像的潜力。
研究设计与样本
- 剂量计算基于多次时间点全身PET/CT显像获得的活性摄取,以及从ICRP 133标准男性和女性数学体模推导的器官特异性剂量学S因子。
- 有效剂量使用最新ICRP组织权重因子计算。
主要发现
- 系列图像和时间-活性曲线显示脑和左心室心肌摄取分别占注射活性的5%和0.65%,脑内滞留高于心肌。
- 平均有效剂量为19.70 ± 2.27 μSv/MBq。
- 标准男性最大吸收剂量位于肝脏(52.91 ± 1.46 μGy/MBq)和心壁(43.94 ± 12.88 μGy/MBq)。
- 标准女性最大吸收剂量位于肝脏(61.66 ± 13.61 μGy/MBq)和肺(40.93 ± 3.11 μGy/MBq)。
- 所有器官的吸收剂量,尤其是红骨髓(20.03 ± 2.89 μGy/MBq),足够低,可确保多次随访检查后无毒性。
关键数值与推荐
- 平均有效剂量为19.70 ± 2.27 μSv/MBq。
- 标准男性肝脏吸收剂量为52.91 ± 1.46 μGy/MBq,心壁为43.94 ± 12.88 μGy/MBq。
- 标准女性肝脏吸收剂量为61.66 ± 13.61 μGy/MBq,肺为40.93 ± 3.11 μGy/MBq。
- 红骨髓吸收剂量为20.03 ± 2.89 μGy/MBq。
- 脑和左心室心肌摄取分别占注射活性的5%和0.65%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 4-[18F] fluorobenzyl dexetimide (F-DEX) is the first non-subtype selective fluorine-18 labelled tracer for muscarinic receptors (mAChR) used in humans. A recent first-in-human study found high regional brain uptake with low variation in normal subjects. Disturbance of mAChR has been reported in Alzheimer's and Parkinson's disease, schizophrenia and depression and various cardiac diseases. The following work assesses the biodistribution, organ tracer kinetics and radiation dose associated with F-DEX. METHOD: Dose calculations were based on activity uptake derived from multiple time point whole body PET CT imaging and the organ-specific dosimetric S-factors derived from the ICRP 133 standard man and woman mathematical phantoms. Effective doses were calculated using the latest ICRP tissue weighting factors. RESULTS: Serial images and time activity curves demonstrate high brain and left ventricular myocardial uptake (5% and 0.65% of injected activity, respectively) with greater retention in brain than myocardium. The mean effective dose was in concordance with other 18F labelled tracers at 19.70 ± 2.27 μSv/MBq. The largest absorbed doses were in the liver (52.91 ± 1.46 μGy/MBq) and heart wall (43.94 ± 12.88 μGy/MBq) for standard man and the liver (61.66 ± 13.61 μGy/MBq) and lungs (40.93 ± 3.11 μGy/MBq) for standard woman. The absorbed dose to all organs, most notably, the red bone marrow (20.03 ± 2.89 μGy/MBq) was sufficiently low to ensure no toxicity after numerous follow-up procedures. CONCLUSIONS: The radiation dose associated with an administration of F-DEX is comparable to that of other 18F labelled tracers such as FDG (19.0 μSv/MBq) and lower than tracers used for SPECT imaging of muscarinic receptors (I-DEX 28.5 μSv/MBq). Clinical use would likely result in an effective dose less than 4 mSv for the ICRP 133 standard phantoms after dose optimisation allowing justification for numerous follow-up procedures. Recent results from first in-human studies and a comparatively low radiation dose make F-DEX an attractive option for future applications of imaging muscarinic receptors in the brain. Further investigation of the potential of F-DEX for imaging parasympathetic innervation of the heart may be warranted.
引用
- Pain CD, O'Keefe GJ, Ackermann U, et al. Human biodistribution and internal dosimetry of 4-[ 18F]fluorobenzyl-dexetimide: a PET radiopharmaceutical for imaging muscarinic acetylcholine receptors in the brain and heart. EJNMMI Res. 2020. PMID: 32533449. doi:10.1186/s13550-020-00641-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。